Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479558 | 0.82 | LMNA (0.61) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL4465721 | 0.80 | TDP1 (0.47) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL4461393 | 0.79 | MAPT (0.51) | ALDH1A1LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL6270330 | 0.77 | MAPT (1.00) | ALDH1A1LMNAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL6263506 | 0.77 | MAPT (1.00) | ALDH1A1LMNAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL21449555 | 0.77 | CYP1A2 (0.57) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL4466630 | 0.74 | MAPT (0.53) | ALDH1A1MAPTCYP2C9CYP2C19GAA | |
| SCHEMBL22305400 | 0.72 | TSHR (0.80) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL11715149 | 0.72 | TSHR (0.80) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL4473676 | 0.70 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| CN-101296924-A | Pyrazole-isoquinoline urea derivatives as P38 kinase inhibitors | LILLY CO ELI (US) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943244-A1 | PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053346-A1 | PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | CNKSR1, CHUK, SLC14A1 | ALDH1A1 1769/4885LMNA 3226/4885MAPT 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.